SAN DIEGO, June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments..

圣地亚哥，2024年6月4日/PRNewswire/--DNA测序和基于阵列的技术的全球领导者Illumina Inc.（纳斯达克：ILMN）宣布，它已经完成了将其最新化学物质XLEAP-SBS™整合到其NextSeq™1000和NextSeq 2000下一代测序（NGS）仪器的所有试剂中。。

'We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit,' said Jason Johnson, head of Global Product Management at Illumina. 'XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches.'.

Illumina全球产品管理负责人杰森·约翰逊（JasonJohnson）说：“我们很高兴能为我们的NextSeq 1000/2000客户提供改进的测序，更快的运行时间，更好的质量和更高的产量，所有这些都是以更低的套件成本实现的。”NextSeq 1000/2000上的XLEAP-SBS化学将使实验室能够在不增加预算的情况下执行更大的NGS项目，并促进更多地采用多组学方法。”。

In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry for the NextSeq 2000, and today it announced that the XLEAP-SBS P1, P2, and P3 flow cells are all now available. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times..

3月，该公司为NextSeq 2000推出了带有XLEAP-SBS化学的P4流通池（最高输出540 Gb），今天它宣布XLEAP-SBS P1、P2和P3流通池现已全部上市。XLEAP-SBS化学是一种更快，更高质量，更强大的合成测序化学，可将周转时间缩短约20%。。

Early-access customers have shared positive feedback on improved quality, stability, and run times. Marc Monot, PhD, head of Biomics at the Institut Pasteur, said, 'We were very happy with the quantity and quality of the reads. The Q is very close to Q40 and the stability is a game changer for Illumina.

早期访问客户对改进的质量、稳定性和运行时间都有积极的反馈。巴斯德研究所（InstitutPasteur）生物医学负责人马克·莫诺（MarcMonot）博士说，“我们对阅读的数量和质量感到非常满意。Q非常接近Q40，稳定性是Illumina改变游戏规则的因素。

From the first base to the last base, [Illumina] improved the quality of the run quite a lot.'The NextSeq 1000 and NextSeq 2000 Systems are flexible and scalable mid-throughout sequencers that enable a range of applications, including single-cell, whole-exome, and RNA sequencing.Use of forward-looking statementsThis release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs.

从一垒到最后一垒，[Illumina]大大提高了跑动质量。”NextSeq 1000和NextSeq 2000系统是灵活且可扩展的中端测序仪，可实现一系列应用，包括单细胞，全外显子组和RNA测序。前瞻性声明的使用本版本包含涉及风险和不确定性的前瞻性声明，包括与存储和管理基因组数据成本相关的较低成本预期。

Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including meeting manufacturing, quality, and performance requirements; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand.

可能导致实际结果与任何前瞻性陈述中的结果存在重大差异的重要因素包括：（i）开发和推出新产品和服务所固有的挑战，包括满足制造、质量和性能要求；（ii）我们部署新产品、服务和应用程序的能力，以及为我们的技术平台拓展市场的能力；（iii）客户接受我们新推出的产品，这些产品一旦部署，可能会或可能不会满足我们和他们的期望，以及我们向证券交易委员会提交的文件中详述的其他因素，包括我们最近在表格10-K和10-Q中提交的文件，或在公开电话会议中披露的信息，这些信息的日期和时间是事先发布的。

We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the pr.

我们没有义务也不打算更新这些前瞻性声明，审查或确认分析师的预期，或提供中期报告或公共关系的更新。